Beyond Blood Sugar: How Semaglutide and Tirzepatide Are Rewriting Cardiometabolic Medicine
A new wave of 2025 research suggests GLP-1 and dual GIP/GLP-1 drugs do more than shrink waistlines and tame A1c — they may protect the heart at the cellular level, and hint at effects we are only beginning to map.